Indianapolis, IN, United States of America

Barry A Dreikorn


Average Co-Inventor Count = 1.8

ph-index = 7

Forward Citations = 163(Granted Patents)


Location History:

  • Indianapolis, IN (US) (1976 - 1983)
  • Oxfordshire, GB (1993)
  • Marcham, Oxfordshire, GB (1994)
  • Lawrence, IN (US) (1983 - 1995)

Company Filing History:


Years Active: 1976-1995

Loading Chart...
22 patents (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Barry A. Dreikorn

Introduction: Barry A. Dreikorn, an accomplished inventor based in Indianapolis, Indiana, has made significant contributions to the field of pharmaceutical chemistry. With a remarkable portfolio of 22 patents, Dreikorn's work focuses primarily on quinazoline derivatives, which have valuable applications in medicinal chemistry.

Latest Patents: Among his latest innovations, Dreikorn has developed a class of substituted quinazolines, represented by complex chemical structures. These compounds exhibit a variety of substituents, including hydrogen, halo groups, and alkyl chains, which can enhance their therapeutic potential. His work also includes the synthesis of 4-(2-(4-(2-pyridinyloxy)phenyl)ethoxy)quinazoline and its analogues. These compounds feature heterocycles such as pyridyl, pyrazinyl, and pyrimidinyl, all of which are designed to optimize efficacy in medicinal applications.

Career Highlights: Barry's impressive career includes pivotal roles at prominent companies such as Eli Lilly and Company and Dowelanco. His experiences in these reputable organizations have honed his expertise in drug development and innovation, significantly contributing to his extensive patent portfolio.

Collaborations: Throughout his career, Barry A. Dreikorn has collaborated with esteemed colleagues, including Robert G. Suhr and Glen P. Jourdan. Their combined efforts have resulted in groundbreaking research and advancements in the field of medicinal chemistry, showcasing the importance of teamwork in achieving innovative results.

Conclusion: Barry A. Dreikorn stands as a notable figure in the realm of inventions, with a strong focus on the development of quinazoline derivatives. His 22 patents reflect his dedication to enhancing pharmaceutical science, and his collaborations with industry professionals further emphasize his impact on innovations in the field. As he continues his work, Dreikorn is sure to inspire future generations of inventors and researchers alike.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…